title: How allosteric effectors can bind to the same protein residue and produce opposite shifts in the allosteric equilibrium.
abstract: Monoaldehyde allosteric effectors of hemoglobin were designed, using molecular modeling software (GRID), to form a Schiff base adduct with the Val 1 alpha N-terminal nitrogens and interact via a salt bridge with Arg 141 alpha of the opposite subunit. The designed molecules were synthesized if not available. It was envisioned that the molecules, which are aldehyde acids, would produce a high-affinity hemoglobin with potential interest as antisickling agents similar to other aldehyde acids reported earlier. X-ray crystallographic analysis indicated that the aldehyde acids did bind as modeled de novo in symmetry-related pairs to the alpha subunit N-terminal nitrogens. However, oxygen equilibrium curves run on solutions obtained from T- (tense) state hemoglobin crystals of reacted effector molecules produced low-affinity hemoglobins. The shift in the allosteric equilibrium was opposite to that expected. We conclude that the observed shift in allosteric equilibrium was due to the acid group on the monoaldehyde aromatic ring that forms a salt bridge with the guanidinium ion of Arg 141 alpha on the opposite subunit. This added constraint to the T-state structure that ties two subunits across the molecular symmetry axis shifts the equilibrium further toward the T-state. We tested this idea by comparing aldehydes that form Schiff base interactions with the same Val 1 alpha residues but do not interact across the dimer subunit symmetry axis (a new one in this study with no acid group and others that have had determined crystal structures). The latter aldehydes shift the allosteric equilibrium toward the R-state. A hypothesis to predict the direction in shift of the allosteric equilibrium is made and indicates that it is not exclusively where the molecule binds but how it interacts with the protein to stabilize or destabilize the T- (tense) allosteric state.
authors.affiliation: Department of Medicinal Chemistry, School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0540, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: Abraham
authors.forename: M K
authors.initials: MK
authors.lastname: Safo
authors.forename: T
authors.initials: T
authors.lastname: Boyiri
authors.forename: R E
authors.initials: RE
authors.lastname: Danso-Danquah
authors.forename: J
authors.initials: J
authors.lastname: Kister
authors.forename: C
authors.initials: C
authors.lastname: Poyart
mesh_terms: D000447:Aldehydes / Q000737:chemistry / Q000378:metabolism*; D000494:Allosteric Regulation; D000495:Allosteric Site; D000595:Amino Acid Sequence; D001547:Benzaldehydes / Q000737:chemistry / Q000378:metabolism; D003198:Computer Simulation; D003460:Crystallization; D018360:Crystallography, X-Ray; D006441:Hemoglobin A / Q000378:metabolism*; D007525:Isoelectric Focusing; D009682:Magnetic Resonance Spectroscopy; D008958:Models, Molecular; D008969:Molecular Sequence Data; D015394:Molecular Structure; D010100:Oxygen / Q000378:metabolism; D012459:Salicylates / Q000737:chemistry / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D000447:Aldehydes; D001547:Benzaldehydes; D012459:Salicylates; C096871:3,5-dimethyl-4-hydroxybenzaldehyde; D006441:Hemoglobin A; D010100:Oxygen